Open Alliance - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Open Alliance
A round table with Catalent and BASF on their new collaboration to provide bioavailability solutions.

Pharmaceutical Technology Europe
Volume 24, Issue 9

In early 2012, BASF and Catalent formed an open alliance aimed at providing solutions for bioavailability. To understand the details of the collaboration and its goals, we spoke to representatives at each company. Participating in the round table were: Martin Widmann, Senior Vice-President of Pharma Ingredients & Services at BASF and Ian Muir, PhD, President of Modified Release Technologies at Catalent.

Q. Can you explain what each company is contributing to the alliance and how the collaboration functions?

Widmann: BASF and Catalent have complementary offerings and knowledge that address the same customer needs: the enhancement of solubility and bioavailability of poorly soluble drugs. BASF has the broadest portfolio of solubilizers in the industry.

Below left to right: Ian Muir, Catalent, and Martin Widmann, BASF.
Muir: Together, we will build efficiencies for our customers along the value chain from formulation development and ingredient selection through manufacturing process selection to the finished dosage form—bringing more products and better treatments faster to the market. Catalent has 75 years of heritage enhancing bioavailability with our Softgel technology and has recently expanded its OptiMelt™ hot-melt extrusion capabilities in the US and its Schorndorf, Germany, facility.

Q. The collaboration joins two companies with formulation development and manufacturing expertise. How does the collaboration go beyond a traditional supply relationship? What is meant by an open alliance?

Widmann: "Open" means that both partners have joined forces on a nonexclusive basis, because we think that this is the most efficient approach to the market and one that maximizes the reach of both companies. The idea is to provide support in excipient selection for a particular customer need and to provide access to Catalent's formulation and manufacturing experts and leading drug delivery technologies.

Muir: Catalent wants to keep full flexibility in the choice of excipients for its customers, and the open alliance arrangement ensures that customers are not limited to the excipient portfolio of one supplier. The major advantage of the BASF portfolio is the access to its different chemistries, which makes matching to optimize solubility all the more likely. The open alliance will provide customers with formulation expertise across BASF and Catalent and in turn offer seamless bioavailability enhancement solutions from molecule to market.

Q. The alliance was specifically formed to respond to client problems in resolving problems of bioavailability of BCS Class II and IV poorly soluble compounds. What are the potential solutions that can be used to resolve these challenges from an excipient and technology perspective?

Muir: Catalent is the leading industry partner in the development and formulation of drugs, biologics and consumer health products and a world leader in drug delivery technology. Bioavailability enhancement can be addressed through multiple approaches, including optimizing the API, formulation, processing technology, and/or drug delivery dosage form. Our technologies range from OptiForm™ high throughput screening to Softgel technology and OptiMelt™ hot-melt extrusion to highly differentiated controlled release tableting technologies such as OSDrC OptiDose™.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here